Does the media prefer IRTC or ENOV?

In the previous week, Enovis had 9 more articles in the media than iRhythm Technologies. MarketBeat recorded 10 mentions for Enovis and 1 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.66 beat Enovis' score of 0.11 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PLSE or ENOV more profitable?

Enovis has a net margin of -47.96% compared to Pulse Biosciences' net margin of -6,755.78%. Enovis' return on equity of 12.03% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences -6,755.78% -94.42% -79.96% Enovis -47.96% 12.03% 4.91%

Does the media prefer PLSE or ENOV?

In the previous week, Enovis had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 10 mentions for Enovis and 6 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.39 beat Enovis' score of 0.11 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enovis 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is TMDX or ENOV more profitable?

TransMedics Group has a net margin of 22.69% compared to Enovis' net margin of -47.96%. TransMedics Group's return on equity of 15.88% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets TransMedics Group 22.69% 15.88% 5.95% Enovis -47.96% 12.03% 4.91%

Does the media prefer TMDX or ENOV?

In the previous week, TransMedics Group had 1 more articles in the media than Enovis. MarketBeat recorded 11 mentions for TransMedics Group and 10 mentions for Enovis. TransMedics Group's average media sentiment score of 0.73 beat Enovis' score of 0.11 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ATRC or ENOV?

AtriCure has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.53 -$11.45M $0.21 276.67 Enovis $2.25B 0.46 -$1.18B -$19.26 N/A

Is ATRC or ENOV more profitable?

AtriCure has a net margin of 1.85% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Enovis -47.96% 12.03% 4.91%

Does the media prefer ATRC or ENOV?

In the previous week, Enovis had 5 more articles in the media than AtriCure. MarketBeat recorded 10 mentions for Enovis and 5 mentions for AtriCure. AtriCure's average media sentiment score of 0.93 beat Enovis' score of 0.11 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, AXGN or ENOV?

AxoGen has higher earnings, but lower revenue than Enovis. AxoGen is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.56 -$15.70M -$0.68 N/A Enovis $2.25B 0.46 -$1.18B -$19.26 N/A

Is AXGN or ENOV more profitable?

AxoGen has a net margin of -13.36% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Enovis -47.96% 12.03% 4.91%

Does the media prefer AXGN or ENOV?

In the previous week, Enovis had 8 more articles in the media than AxoGen. MarketBeat recorded 10 mentions for Enovis and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.51 beat Enovis' score of 0.11 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Enovis (ENOV) Competitors

$18.03 -0.01 (-0.06%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$18.03 +0.00 (+0.01%)

As of 04:25 AM Eastern

Compare

ENOV vs. IRTC, PLSE, TMDX, ATRC, and AXGN

Should you buy Enovis stock or one of its competitors? Enovis's main competitors and comparable companies include iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), TransMedics Group (TMDX), AtriCure (ATRC), and AxoGen (AXGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Enovis compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

98.5% of Enovis shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Enovis had 9 more articles in the media than iRhythm Technologies. MarketBeat recorded 10 mentions for Enovis and 1 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.66 beat Enovis' score of 0.11 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

iRhythm Technologies has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Enovis has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

iRhythm Technologies has higher earnings, but lower revenue than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.82	-$44.55M	-$0.43	N/A
Enovis	$2.25B	0.46	-$1.18B	-$19.26	N/A

iRhythm Technologies has a net margin of -1.69% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Enovis	-47.96%	12.03%	4.91%

iRhythm Technologies currently has a consensus price target of $179.93, indicating a potential upside of 64.57%. Enovis has a consensus price target of $40.38, indicating a potential upside of 123.94%. Given Enovis' higher possible upside, analysts clearly believe Enovis is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

iRhythm Technologies and Enovis tied by winning 8 of the 16 factors compared between the two stocks.

How does Enovis compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Enovis had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 10 mentions for Enovis and 6 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.39 beat Enovis' score of 0.11 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Enovis has a net margin of -47.96% compared to Pulse Biosciences' net margin of -6,755.78%. Enovis' return on equity of 12.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Enovis	-47.96%	12.03%	4.91%

Pulse Biosciences has higher earnings, but lower revenue than Enovis. Pulse Biosciences is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,897.13	-$72.78M	-$1.18	N/A
Enovis	$2.25B	0.46	-$1.18B	-$19.26	N/A

Pulse Biosciences currently has a consensus price target of $45.25, indicating a potential downside of 16.00%. Enovis has a consensus price target of $40.38, indicating a potential upside of 123.94%. Given Enovis' higher possible upside, analysts plainly believe Enovis is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Pulse Biosciences has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Enovis has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Summary

Enovis beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

TransMedics Group has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$668.47M	4.47	$190.29M	$3.89	22.22
Enovis	$2.25B	0.46	-$1.18B	-$19.26	N/A

TransMedics Group has a net margin of 22.69% compared to Enovis' net margin of -47.96%. TransMedics Group's return on equity of 15.88% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Enovis	-47.96%	12.03%	4.91%

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Enovis has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

TransMedics Group presently has a consensus target price of $121.10, suggesting a potential upside of 40.13%. Enovis has a consensus target price of $40.38, suggesting a potential upside of 123.94%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, TransMedics Group had 1 more articles in the media than Enovis. MarketBeat recorded 11 mentions for TransMedics Group and 10 mentions for Enovis. TransMedics Group's average media sentiment score of 0.73 beat Enovis' score of 0.11 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

TransMedics Group beats Enovis on 12 of the 16 factors compared between the two stocks.

How does Enovis compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

99.1% of AtriCure shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AtriCure presently has a consensus target price of $53.30, indicating a potential downside of 8.26%. Enovis has a consensus target price of $40.38, indicating a potential upside of 123.94%. Given Enovis' higher probable upside, analysts clearly believe Enovis is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

AtriCure has a net margin of 1.85% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Enovis	-47.96%	12.03%	4.91%

AtriCure has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67
Enovis	$2.25B	0.46	-$1.18B	-$19.26	N/A

In the previous week, Enovis had 5 more articles in the media than AtriCure. MarketBeat recorded 10 mentions for Enovis and 5 mentions for AtriCure. AtriCure's average media sentiment score of 0.93 beat Enovis' score of 0.11 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

AtriCure has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Enovis has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Summary

AtriCure beats Enovis on 9 of the 16 factors compared between the two stocks.

How does Enovis compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

AxoGen has higher earnings, but lower revenue than Enovis. AxoGen is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.56	-$15.70M	-$0.68	N/A
Enovis	$2.25B	0.46	-$1.18B	-$19.26	N/A

In the previous week, Enovis had 8 more articles in the media than AxoGen. MarketBeat recorded 10 mentions for Enovis and 2 mentions for AxoGen. AxoGen's average media sentiment score of 0.51 beat Enovis' score of 0.11 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AxoGen currently has a consensus price target of $51.56, indicating a potential upside of 16.56%. Enovis has a consensus price target of $40.38, indicating a potential upside of 123.94%. Given Enovis' higher possible upside, analysts plainly believe Enovis is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

AxoGen has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Enovis has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

AxoGen has a net margin of -13.36% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Enovis	-47.96%	12.03%	4.91%

Summary

Enovis beats AxoGen on 9 of the 14 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.04B	$5.49B	$7.22B	$23.04B
Dividend Yield	N/A	1.80%	2.57%	3.62%
P/E Ratio	-0.94	25.34	275.48	28.21
Price / Sales	0.46	72.80	653.49	22.51
Price / Cash	0.67	33.11	28.13	19.32
Price / Book	0.69	5.90	10.57	4.70
Net Income	-$1.18B	$151.55M	$3.49B	$1.07B
7 Day Performance	-0.78%	0.23%	-0.23%	-1.26%
1 Month Performance	-31.24%	-3.83%	-2.67%	-4.29%
1 Year Performance	-44.30%	6.90%	18.17%	8.41%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	3.7266 of 5 stars	$18.03 -0.1%	$40.38 +123.9%	-44.3%	$1.04B	$2.25B	N/A	7,802	Analyst Downgrade
IRTC iRhythm Technologies	3.9155 of 5 stars	$123.07 flat	$179.93 +46.2%	-37.5%	$4.06B	$747.14M	N/A	2,400	Positive News
PLSE Pulse Biosciences	1.6391 of 5 stars	$53.24 flat	$45.25 -15.0%	+205.9%	$3.68B	$350K	N/A	140	Positive News
TMDX TransMedics Group	4.6007 of 5 stars	$89.98 flat	$124.18 +38.0%	-29.3%	$3.11B	$605.49M	23.13	210	Positive News Gap Down
ATRC AtriCure	2.5335 of 5 stars	$51.52 flat	$52.00 +0.9%	+59.5%	$2.62B	$534.53M	245.35	1,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors

ENOV vs. IRTC, PLSE, TMDX, ATRC, and AXGN

How does Enovis compare to iRhythm Technologies?

Summary

How does Enovis compare to Pulse Biosciences?

Summary

How does Enovis compare to TransMedics Group?

Summary

How does Enovis compare to AtriCure?

Summary

How does Enovis compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enovis (ENOV) Competitors

ENOV vs. IRTC, PLSE, TMDX, ATRC, and AXGN

How does Enovis compare to iRhythm Technologies?

Do institutionals & insiders believe in IRTC or ENOV?

Does the media prefer IRTC or ENOV?

Which has more risk and volatility, IRTC or ENOV?

Which has higher earnings & valuation, IRTC or ENOV?

Is IRTC or ENOV more profitable?

Do analysts recommend IRTC or ENOV?

Summary

How does Enovis compare to Pulse Biosciences?

Do insiders & institutionals hold more shares of PLSE or ENOV?

Does the media prefer PLSE or ENOV?

Is PLSE or ENOV more profitable?

Which has preferable valuation and earnings, PLSE or ENOV?

Do analysts prefer PLSE or ENOV?

Which has more volatility and risk, PLSE or ENOV?

Summary

How does Enovis compare to TransMedics Group?

Which has better valuation and earnings, TMDX or ENOV?

Is TMDX or ENOV more profitable?

Do insiders and institutionals have more ownership in TMDX or ENOV?

Which has more volatility & risk, TMDX or ENOV?

Do analysts prefer TMDX or ENOV?

Does the media prefer TMDX or ENOV?

Summary

How does Enovis compare to AtriCure?

Do insiders & institutionals hold more shares of ATRC or ENOV?

Do analysts recommend ATRC or ENOV?

Is ATRC or ENOV more profitable?

Which has stronger earnings and valuation, ATRC or ENOV?

Does the media prefer ATRC or ENOV?

Which has more risk & volatility, ATRC or ENOV?

Summary

How does Enovis compare to AxoGen?

Which has stronger valuation & earnings, AXGN or ENOV?

Does the media prefer AXGN or ENOV?

Do institutionals & insiders believe in AXGN or ENOV?

Do analysts prefer AXGN or ENOV?

Which has more risk and volatility, AXGN or ENOV?

Is AXGN or ENOV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools